Ultragenyx reviews apazunersen and plans cost cuts after Phase 3 miss
Ultragenyx said it will reduce expenses and evaluate its development of apazunersen after the drug failed to meet its primary endpoint in a Phase 3 trial, which targeted improved cognitive scores in Angelman syndrome patients.